Peptides vs. Steroids: The 10-Year Horizon

The Concept of Hormonal Debt

Every time you introduce an exogenous compound, you're taking out a loan against your endocrine system. The real question is about the interest rate and the payback period. Anabolic-androgenic steroids (AAS) are like a high-interest loan. You get the cash (anabolism) upfront, but the debt can be substantial, and repayment through post-cycle therapy (PCT) can take months.

The reason is that AAS work by directly replacing or overwhelming your body's natural testosterone. You're dumping the finished product into the system. Your hypothalamic-pituitary-testicular axis (HPTA) sees this surplus of androgens and does exactly what it's designed to do: it shuts down production. It stops sending the signals (GnRH, LH, FSH) to your testes. Stop the cycle, and you're left with a silent factory and a slow process of getting the machinery running again.

How often it fully restarts is disputed. The Dutch HAARLEM cohort of amateur athletes found gonadal function recovered in most men after they stopped. A 2021 review of published case reports found full recovery in only 4 of 38 cases with known outcomes, but case reports skew toward men who sought care because they didn't recover.

Most peptides, particularly the growth hormone secretagogues, operate on a different principle. They're not the finished product. They're the foreman yelling at the factory workers to speed up for a shift. Ipamorelin (which acts on the ghrelin receptor) and tesamorelin (a GHRH analogue) stimulate your pituitary to release your own growth hormone in pulses, and the body's normal feedback on that release stays in place. They don't act on the testosterone axis. When the peptide is cleared, the foreman goes home.

That doesn't mean there's no debt, only that it sits on a different account and is much less studied. Nobody has followed peptide users for ten years. It's the difference between hijacking one system and pushing hard on another.

Organ Health: Precision Tools vs. Sledgehammers

Livers, hearts, kidneys: the organs that keep you alive long after your bench press PR is a distant memory. This is where the long-term cost of AAS is best documented.

Oral steroids are notoriously hepatotoxic because of a chemical modification called 17-alpha alkylation. This tweak allows the compound to survive the first pass through the liver, but it strains the liver in the process, which shows up as raised liver enzymes (ALT/AST). Injectable AAS are easier on the liver, but they aren't benign. In the HAARLEM cohort, the measured impact on liver and kidney function was real but limited.

The bigger concern is cardiovascular health. AAS act on androgen receptors throughout the body, including in the heart and blood vessels. A 2010 review of 49 studies covering 1,467 athletes (mostly small and retrospective, with some conflicting results) linked AAS use with:

• Worse lipids: higher LDL (bad) cholesterol and lower HDL (good) cholesterol.
• Higher blood pressure: both systolic and diastolic, although the studies disagree.
• Left Ventricular Hypertrophy (LVH): a thickening of the heart muscle wall that may persist after AAS are stopped.

A 2017 study in Circulation compared 86 weightlifters with at least two years of AAS use to 54 non-users. Users had weaker heart pumping (mean ejection fraction 52% vs. 63%) and more coronary plaque, which rose with years of use.

Peptides are often called precision tools, and on mechanism that's partly fair. In rodent studies, BPC-157 appears to act mainly on pathways related to angiogenesis and tissue repair. Ipamorelin was named "the first selective growth hormone secretagogue" in its 1998 paper because, in pigs, it raised growth hormone without raising ACTH or cortisol. But selectivity in animals isn't a clean safety record in people:

• Ipamorelin: in a Phase 2 trial of 117 adults given IV ipamorelin or placebo for up to 7 days after abdominal surgery, the ipamorelin group had more hypokalemia, insomnia and hyperglycemia, plus 2 deaths after treatment (causality unclear), according to FDA's October 2024 review. FDA found no published repeat-dose toxicity or carcinogenicity studies.
• MK-677 (ibutamoren): an oral ghrelin mimetic, not a peptide, acting on the same receptor. In a 2-year trial of 25 mg daily in 65 healthy adults aged 60-81, fasting glucose rose about 5 mg/dL and insulin sensitivity fell. A trial at the same dose in 123 older hip-fracture patients was stopped early over a congestive heart failure signal.
• BPC-157: a 2025 systematic review found 35 of its 36 studies were preclinical and found no clinical safety data.

Now, this isn't a get-out-of-jail-free card. Pushing GH/IGF-1 levels to the supraphysiological end for years on end could worsen insulin sensitivity (already seen in short trials) and, in theory, affect cell proliferation. The AAS risks also look larger partly because far more people have used AAS for longer, and researchers have followed them.

The 'Keepability' Factor

Many AAS users find that a good share of what they gained on a cycle disappears when they stop. Lifters commonly describe much of the size from a heavy cycle as water and glycogen, which fall away when the exogenous hormone is withdrawn. With a suppressed HPTA, testosterone stays low for weeks or longer after a cycle, which makes holding on to muscle harder. PCT is meant to shorten that window.

Peptide-driven progress is slower and smaller, and the idea that it's more permanent hasn't been tested. In the MK-677 trial, fat-free mass rose about 1.1 kg versus a small loss on placebo, but strength and function didn't change. No trial has measured muscle gain from ipamorelin or CJC-1295 in healthy lifters, and BPC-157's recovery reputation rests mostly on rodent studies. What does follow from the mechanism is that stopping a secretagogue shouldn't cause a hormonal crash like post-cycle hypogonadism. The tissue you built through training and diet is what remains either way.

Where This Leaves Us

Nobody argues that a cycle of CJC-1295 and ipamorelin will add 25 pounds like a testosterone and Dianabol cycle can. As we cover in our piece on why peptides and AAS aren't direct competitors, they're not doing the same job. AAS are effective and come with a well-documented list of serious long-term health risks.

The case that peptides are safer over the long term rests mostly on mechanism: they don't shut down testosterone production, and they don't carry the 17-alpha alkyl group that strains the liver. That's a reasonable argument, but it isn't evidence. Human safety data for most performance peptides cover days to weeks, and the trials that exist found real signals, such as higher blood sugar.

For the athlete thinking about health in ten or twenty years, the choice is between a known, substantial risk (AAS) and one that is probably smaller for most peptides but largely unmeasured. Our guide to how users structure peptide cycles covers the on/off schedules people describe. As of October 2026, WADA prohibits both classes at all times, and the legal picture for peptide use differs from that for steroids.

Comparison table